胸腔内灌注顺铂序贯恩度治疗对乳腺癌恶性胸腔积液的疗效观察  

Curative effect of intrapleural infusion of cisplatin and sequential endostar on malignant pleural effusion of breast cancer

作　　者：张羽 Zhang Yu

机构地区：[1]夏邑县第二人民医院肿瘤科,476400

出　　处：《中国疗养医学》2021年第2期196-198,共3页Chinese Journal of Convalescent Medicine

摘　　要：目的探讨胸腔内灌注顺铂序贯恩度治疗对乳腺癌恶性胸腔积液的临床疗效。方法选择2019年3月至2020年3月某院收治乳腺癌恶性胸腔积液患者80例为研究对象,按照随机数字表分为观察组与对照组,每组各40例。对照组实施胸腔内灌注顺铂治疗,观察组实施胸腔内灌注顺铂序贯恩度治疗。比较两组临床疗效、生存率及不良反应发生情况,同时观察两组治疗前后血管内皮生长因子(VEGF)水平变化。结果观察组治疗总有效率(82.50%)较对照组(42.50%)高,差异有高度统计学意义(χ2=13.653,P<0.001);观察组VEGF(549.65±186.69)ng/L水平较对照组(684.59±198.76)ng/L低,差异有统计学意义(t=3.130,P=0.003);观察组不良反应发生率(17.50%)与对照组(15.00%)相比,差异无统计学意义(χ2=0.092,P=0.762);观察组随访6个月与随访1年的生存率(95.00%、85.00%)均较对照组(87.50%、72.50%)高,但组间比较,差异无统计学意义(χ2=0.626、1.867,P=0.235、0.172)。结论胸腔内灌注顺铂序贯恩度治疗乳腺癌恶性胸腔积液患者的临床效果显著,可有效提高临床总有效率与生存率,降低VEGF水平,且具有一定安全性。Objective To investigate the clinical effect of intrapleural infusion of cisplatin and sequential endostar on malignant pleural effusion of breast cancer.Methods Eighty patients with malignant pleural effusion of breast cancer admitted to a hospital from March 2019 to March 2020 were selected as study subjects,and were divided into observation group and control group according to the random number table method,with 40 patients in each group.The control group received intrathoracic infusion of cisplatin,while the observation group received intrapleural infusion of cisplatin and sequential endostar.The clinical effect,survival rate and adverse reactions of the two groups were compared,and the changes of vascular endothelial growth factor(VEGF)evel before and after treatment were observed.Results The total effective rate in the observation group(82.50%)was higher than that in the control group(42.50%),and the difference was statistically significant(χ2=13.653,P<0.001).The level of VEGF(549.65±186.69)in the observation group was lower than that in the control group(684.59±198.76),and the difference was statistically significant(t=3.130,P=0.003).There was no statistical difference in the incidence of adverse reactions between the observation group(17.50%)and the control group(15.00%)(χ2=0.092,P=0.762).The 6-month and 1-year survival rates(95.00%,85.00%)in the observation group were higher than those in the control group(87.50%,72.50%),but there was no significant difference between the two groups(χ2=0.626,1.867,P=0.235,0.172).Conclusion Intrapleural infusion of cisplatin and sequential endostar in the treatment of malignant pleural effusion among breast cancer patients has significant clinical effects,which can effectively improve the clinical efficiency and survival rate,reduce the level of VEGF,and has a certain safety.

关 键 词：乳腺癌 恶性胸腔积液 胸腔内灌注 顺铂 恩度 血管内皮生长因子 

分 类 号：R737.9[医药卫生—肿瘤]